Skip to main content
Premium Trial:

Request an Annual Quote

Applied DNA Sciences Taps GenXys for PGx Clinical Decision Support Software

NEW YORK – Applied DNA Sciences on Tuesday said GenXys Health Care Systems will be its go-to-market partner to integrate results from the company's TR8 PGx pharmacogenomic testing service into clinical decision support software.

Stony Brook, New York-based Applied DNA's TR8 test is designed to identify genetic variants that affect how a patient may respond to various cardiovascular, oncology, psychiatric, infectious disease, and pain management medications. The test, which was recently approved by the New York State Department of Health, analyzes 120 genetic targets across more than 30 genes.

The genetic variants identified by the TR8 test will be processed by GenXys' clinical decision support software to pinpoint and report potential drug-gene interactions to users. Vancouver, British Columbia-based GenXys' suite of software tools are used by health systems, payors, pharmacies, and laboratories for clinical decision support related to medication prescribing.

Genetically informed prescribing can improve patient outcomes and reduce adverse reactions to drugs, which can lead to cost savings, the companies said.

"To realize these benefits, healthcare providers must have easy-to-understand information about potential drug-gene interactions identified by PGx testing," Applied DNA CEO and President James Hayward said in a statement.